At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Cetuximab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction of Cetuximab and Carboplatin in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Cetuximab, Carboplatin, and 1 other intervention for Solid Tumor. Completed, enrolled 34 participants across 8 sites in 2 countries.
Detailed Summary
The primary purpose of this study is to help answer the following research question(s): * To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with carboplatin \[pharmacokinetic (PK) analysis\] * To see if any drug interactions occur between cetuximab and carboplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartJun 2010
Primary CompletionMay 2015
Study CompletionOct 2015
TodayJul 2026
First PostedFeb 5, 2010
Enrollment StartJun 1, 2010
Primary CompletionMay 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 16.4 years ago
Interventions
Cetuximabdrug
Administered Intravenously
Carboplatindrug
Administered Intravenously
5 - FUdrug
Administered Intravenously